Subscribe To

Price Alert Latest News Economic Calendar News

LRMR / Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference

BALA CYNWYD, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will present and participate in 1x1 investor meetings at the 34th Annual Piper Sandler Healthcare Conference, which is taking place in New York, NY from November 29 – December 1, 2022. The Company's presentation will take place on Thursday, December 1, 2022, at 10:10 AM ET. Read More

Demo Live Account See Partner Details

Content Topics

Larimar

Therapeutics

Present

34th

Annual

Piper

Sandler

Healthcare

Conference

Stock

LRMR

Posted: Nov 21 2022, 16:05

Author Name: GlobeNewsWire

LRMR News

By Seeking Alpha
August 2, 2023

Larimar: Friedreich's Ataxia Drug With Significant Potential

Clearance given by FDA to initiate higher 50 mg dosing of CTI-1601 for patients with Friedreich's Ataxia for phase 2 study; results from this cohort e

By Zacks Investment Research
May 9, 2023

Larimar (LRMR) Upgraded to Strong Buy: What Does It Mean for the Stock?

Larimar (LRMR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

By Zacks Investment Research
April 19, 2023

New Strong Buy Stocks for April 19th

SIGA, RYI, LRMR, VRTV and PLL have been added to the Zacks Rank #1 (Strong Buy) List on April 19, 2023.

By Zacks Investment Research
April 12, 2023

Here's Why You Should Invest in Larimar (LRMR) Stock Now

Here we discuss some reasons why investing in Larimar Therapeutics (LRMR) stock now is a good idea.

By GlobeNewsWire
November 21, 2022

Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference

BALA CYNWYD, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.